APA (7th ed.) Citation

Dytfeld, D., Wróbel, T., Jamroziak, K., Kubicki, T., Robak, P., Walter-Croneck, A., . . . Szukalski, Ł. (2023). Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): Interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncology, 24(2), 139. https://doi.org/10.1016/S1470-2045(22)00738-0

Chicago Style (17th ed.) Citation

Dytfeld, Dominik, et al. "Carfilzomib, Lenalidomide, and Dexamethasone or Lenalidomide Alone as Maintenance Therapy After Autologous Stem-cell Transplantation in Patients with Multiple Myeloma (ATLAS): Interim Analysis of a Randomised, Open-label, Phase 3 Trial." Lancet Oncology 24, no. 2 (2023): 139. https://doi.org/10.1016/S1470-2045(22)00738-0.

MLA (9th ed.) Citation

Dytfeld, Dominik, et al. "Carfilzomib, Lenalidomide, and Dexamethasone or Lenalidomide Alone as Maintenance Therapy After Autologous Stem-cell Transplantation in Patients with Multiple Myeloma (ATLAS): Interim Analysis of a Randomised, Open-label, Phase 3 Trial." Lancet Oncology, vol. 24, no. 2, 2023, p. 139, https://doi.org/10.1016/S1470-2045(22)00738-0.